2-Chlorodeoxyadenosine therapy in advanced chronic lymphocytic leukaemia

Area of Science:

• Oncology
• Hematology

Background:

• The efficacy of 2-chlorodeoxyadenosine (CdA) for advanced chronic lymphocytic leukemia (CLL) is debated, with reported response rates varying widely.
• Previous treatments often influence patient outcomes in relapsed or refractory CLL.

Purpose of the Study:

• To evaluate the therapeutic potential and toxicity of 2-chlorodeoxyadenosine (CdA) in a cohort of pretreated chronic lymphocytic leukemia (CLL) patients.
• To identify factors associated with response and adverse events in CLL patients receiving CdA therapy.

Main Methods:

• Retrospective analysis of 22 CLL patients treated with CdA via continuous intravenous infusion (4 mg/m2/day for 7 days) or 2-h infusions (5.6 mg/m2/day for 5 days).
• Assessment of treatment response, including partial and complete responses.
• Evaluation of hematological toxicity, specifically neutropenia and thrombocytopenia, during the first treatment course.

Main Results:

• A total response rate of 32% (7 out of 22 patients) was observed.
• Responding patients had significantly shorter intervals from diagnosis to CdA therapy (58 vs. 102 months) and better baseline platelet counts (165 vs. 81 x 10(9)/L).
• Severe neutropenia (Grade 4) occurred in 7 patients, and severe thrombocytopenia (Grade 4) in one patient. Patients refractory to fludarabine did not respond to CdA.

Conclusions:

• CdA demonstrated a low response rate in heavily pretreated CLL patients, particularly those refractory to fludarabine.
• Earlier administration of CdA and better baseline hematological status were associated with improved treatment outcomes.
• Significant hematological toxicity necessitates careful patient selection and monitoring during CdA therapy.